Furthermore, analysis of several datasets showed that DOCK1 is upregulated in liver cancer (Figs. 5E–G, S5B and S5C), which suggested that the combined treatment of metformin with DOCK1 inhibitor could provide clinical benefits for HCC patients who have high levels of DOCK1. Here, DOCK1 is linked to liver cancer.